SCHEMBL284489

SCHEMBL284489

C1=NCCNCCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780706 1.00 HIF1A (0.33)
SCHEMBL625882 1.00 HIF1A (0.33)
SCHEMBL1781456 1.00 HIF1A (0.33)
SCHEMBL12095338 1.00 HIF1A (0.33)
SCHEMBL6518187 0.97 HIF1A (0.32)
SCHEMBL1782493 0.94
SCHEMBL148995 0.94
SCHEMBL1864746 0.91
SCHEMBL1783195 0.91
SCHEMBL1782807 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055172-A Chimeric radiopharmaceuticals targeting the proton-sensitive receptor GPR4 安菲利克斯股份公司 2026-05-15 CN claimed
EP-4724068-A2 COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF Cytosite Biopharma Inc. (US) 2026-04-15 EP claimed
EP-4719498-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
EP-4619411-A1 DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF Full-Life Technologies HK Limited (HK) 2025-09-24 EP claimed
EP-4556029-A2 RADIOPHARMACEUTICAL CONJUGATE The South African Nuclear Energy Corporation Limited (ZA) 2025-05-21 EP claimed
US-20250136488-A1 Extended- and Multimodal-Release Compositions Finoric LLC 2025-05-01 US claimed
EP-4479040-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF Full-Life Technologies HK Limited (HK) 2024-12-25 EP claimed
WO-2024254417-A2 COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF CYTOSITE BIOPHARMA INC. (US) 2024-12-12 WO claimed
US-9107948-B2 Compounds for diagnosing diseases associated with the expression of MUC5AC GUERBET (FR) 2015-08-18 US claimed
EP-1648510-B1 RG1 ANTIBODIES AND USES THEREOF Bayer Pharma AG (DE) 2013-06-19 EP claimed
US-7893217-B2 Isolated human antibodies that bind epitopes on RG1 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-02-22 US claimed
US-7335748-B2 RG1 antibodies and uses thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-02-26 US claimed
US-20040152139-A1 DNA encoding a novel RG1 polypeptide SCHERING AKTIENGESELLSCHAFT (DE) 2004-08-05 US claimed
WO-2001087354-A2 USE OF SMALL MOLECULE RADIOLIGANDS FOR DIAGNOSTIC IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-11-22 WO claimed
US-5354554-A Crosslinked antibodies and processes for their preparation CELLTECH LIMITED (GB) 1994-10-11 US claimed
EP-0433312-A4 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING 1991-12-04 EP claimed
EP-0433312-A1 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING THE UNIVERSITY OF CONNECTICUT (US) 1991-06-26 EP claimed
WO-1990001900-A1 CARRIER SYSTEM AND METHOD FOR ENHANCEMENT OF MAGNETIC RESONANCE IMAGING THE UNIVERSITY OF CONNECTICUT (US) 1990-03-08 WO claimed